CD38 and Miyoshi myopathy: Anti-CD38 mAbs can promote MM cell death through immune mechanisms, such as complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, amplification of effector T cells, and a reduction in regulatory T cells [88].